Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL217085 | 0.85 | HDAC8 (0.53) | HDAC8HDAC6 | |
| SCHEMBL2645984 | 0.75 | EGLN1 (0.56) | HDAC8HDAC6 | |
| SCHEMBL16199219 | 0.74 | HDAC8 (0.91) | HDAC8HDAC6 | |
| SCHEMBL9453904 | 0.73 | EGLN1 (0.54) | HDAC8HDAC6 | |
| SCHEMBL10465376 | 0.73 | EGLN1 (0.54) | HDAC8HDAC6 | |
| SCHEMBL6627823 | 0.73 | — | — | |
| SCHEMBL21812528 | 0.72 | ADRA1D (0.45) | HDAC6 | |
| SCHEMBL1298229 | 0.71 | — | — | |
| SCHEMBL14328219 | 0.71 | HDAC8 (1.00) | HDAC8HDAC6 | |
| SCHEMBL14328260 | 0.70 | HDAC8 (1.00) | HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222869-A1 | ANTICANCER DRUGS INCLUDING THE CHEMICAL STRUCTURES OF AN ANDROGEN RECEPTOR LIGAND AND A HISTONE DEACETYLASE INHIBITOR | UNITED STATES GOVERNMENT | 2018-08-09 | — | — | US | disclosed |
| WO-2014072714-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LTD (GB) | 2014-05-15 | — | — | WO | disclosed |
| WO-2009141659-A1 | DEPSIPEPTIDES AND THEIR THERAPEUTIC USE | KARUS THERAPEUTICS LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222869-A1 | ANTICANCER DRUGS INCLUDING THE CHEMICAL STRUCTURES OF AN ANDROGEN RECEPTOR LIGAND AND A HISTONE DEACETYLASE INHIBITOR | AR, HDAC1, HDAC11 | HDAC8 8/4885HDAC6 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.